Triptorelin in the management of prostate cancer.

@article{Ploussard2013TriptorelinIT,
  title={Triptorelin in the management of prostate cancer.},
  author={Guillaume Ploussard and Pierre Mongiat-Artus},
  journal={Future oncology},
  year={2013},
  volume={9 1},
  pages={93-102}
}
Among the therapies to achieve medical castration, gonadotropin-releasing hormone (GnRH) agonists have better safety profiles than estrogens and anti-androgens. In addition, slow-release formulations of GnRH agonists offer patients flexibility, improve quality of life and eventually reduce cost. To illustrate the role of medical castration in prostate cancer, this paper reviews data on the GnRH agonist triptorelin long-duration and shorter-duration formulations. A similar proportion of patients… CONTINUE READING

From This Paper

Topics from this paper.
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…